May 21, 2018 / 11:36 AM / 7 months ago

Nabriva's pneumonia drug succeeds in late-stage study

May 21 (Reuters) - Nabriva Therapeutics Plc said on Monday its drug to treat adults suffering from a type of pneumonia met the main goal of a late-stage study.

The company plans to submit a marketing application for the drug, lefamulin, with the U.S. Food and Drug Administration in the fourth quarter of the year. (Reporting by Manas Mishra in Bengaluru; Editing by Sai Sachin Ravikumar)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below